Comirnaty developers Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have submitted to the European Medicines Agency for their Omicron-adapted variant.
Typically around two-thirds of coronavirus vaccines administered in European countries are from the US pharma giant and its German partner.
As countries prepare for colder weather, the ability of Pfizer and its rivals to produce effective Omicron-adapted variants will be crucial to sustaining market share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze